Hubei Jumpcan Pharmaceutical Co Ltd - Asset Resilience Ratio
Hubei Jumpcan Pharmaceutical Co Ltd (600566) has an Asset Resilience Ratio of 48.48% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2025)
This chart shows how Hubei Jumpcan Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Check asset allocation strategy of Hubei Jumpcan Pharmaceutical Co Ltd to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Hubei Jumpcan Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 600566 company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥8.65 Billion | 48.48% |
| Total Liquid Assets | CN¥8.65 Billion | 48.48% |
Asset Resilience Insights
- Very High Liquidity: Hubei Jumpcan Pharmaceutical Co Ltd maintains exceptional liquid asset reserves at 48.48% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Hubei Jumpcan Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Hubei Jumpcan Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
JW Pharmaceutical Corp
KO:001067 |
Drug Manufacturers - Specialty & Generic | 8.17% |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Guilin Sanjin Pharmaceutical Co Ltd
SHE:002275 |
Drug Manufacturers - Specialty & Generic | 14.80% |
|
Fuan Pharmaceutical Group Co
SHE:300194 |
Drug Manufacturers - Specialty & Generic | 1.34% |
|
DRI Healthcare Trust
TO:DHT-U |
Drug Manufacturers - Specialty & Generic | 13.91% |
|
Hainan Shuangcheng Pharmaceut
SHE:002693 |
Drug Manufacturers - Specialty & Generic | 1.03% |
Annual Asset Resilience Ratio for Hubei Jumpcan Pharmaceutical Co Ltd (2002–2025)
The table below shows the annual Asset Resilience Ratio data for Hubei Jumpcan Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 35.40% | CN¥6.27 Billion ≈ $916.85 Million |
CN¥17.70 Billion ≈ $2.59 Billion |
+7.44pp |
| 2024-12-31 | 27.96% | CN¥5.16 Billion ≈ $755.21 Million |
CN¥18.46 Billion ≈ $2.70 Billion |
+10.44pp |
| 2023-12-31 | 17.52% | CN¥3.18 Billion ≈ $465.08 Million |
CN¥18.14 Billion ≈ $2.65 Billion |
-2.81pp |
| 2022-12-31 | 20.32% | CN¥3.04 Billion ≈ $445.51 Million |
CN¥14.98 Billion ≈ $2.19 Billion |
+6.51pp |
| 2021-12-31 | 13.81% | CN¥1.68 Billion ≈ $245.11 Million |
CN¥12.13 Billion ≈ $1.78 Billion |
+1.84pp |
| 2020-12-31 | 11.96% | CN¥1.26 Billion ≈ $184.08 Million |
CN¥10.52 Billion ≈ $1.54 Billion |
+9.77pp |
| 2019-12-31 | 2.19% | CN¥190.00 Million ≈ $27.80 Million |
CN¥8.66 Billion ≈ $1.27 Billion |
-1.50pp |
| 2018-12-31 | 3.69% | CN¥288.00 Million ≈ $42.14 Million |
CN¥7.80 Billion ≈ $1.14 Billion |
-6.39pp |
| 2017-12-31 | 10.09% | CN¥672.00 Million ≈ $98.33 Million |
CN¥6.66 Billion ≈ $974.94 Million |
+5.88pp |
| 2016-12-31 | 4.21% | CN¥210.00 Million ≈ $30.73 Million |
CN¥4.99 Billion ≈ $729.84 Million |
+0.58pp |
| 2015-12-31 | 3.63% | CN¥130.00 Million ≈ $19.02 Million |
CN¥3.59 Billion ≈ $524.66 Million |
-4.71pp |
| 2014-12-31 | 8.34% | CN¥280.00 Million ≈ $40.97 Million |
CN¥3.36 Billion ≈ $491.34 Million |
+8.29pp |
| 2006-12-31 | 0.05% | CN¥400.00K ≈ $58.53K |
CN¥786.51 Million ≈ $115.09 Million |
-5.83pp |
| 2003-12-31 | 5.88% | CN¥38.22 Million ≈ $5.59 Million |
CN¥650.39 Million ≈ $95.17 Million |
-1.38pp |
| 2002-12-31 | 7.26% | CN¥44.08 Million ≈ $6.45 Million |
CN¥607.22 Million ≈ $88.85 Million |
-- |
About Hubei Jumpcan Pharmaceutical Co Ltd
Hubei Jumpcan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of drugs in China. The company offers Chinese traditional and Western medicines, daily use chemicals, and medicine health products in various formulations. Its products are used in the areas of detoxification, digestive system, pediatric, respiratory system, nervous system, anti-infection, cardiovasc… Read more